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Abstract 
Even though years of research on the male contraceptive pill have been conducted, a 
marketable product is still absent from the arsenal of male and female products of 
contraception. In this paper the following psychosocial and cultural factors have been elicited 
from the literature in order to reveal explanations for this delay: acceptability, trust, fear of 
side-effects, perceptions of contraceptive responsibility and fear of losing connotations of 
masculinity. Regardless of cultural variation, overall there seems to be a positive attitude 
towards the acceptability of male contraceptive for both males and females, especially males 
in stable relationships. There has been some indication that the media have played an 
important role in distorting the results of research regarding male and female trust. Ongoing 
and future research into several projects on psychosocial and cultural factors is described. 
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Introduction 
Choices in male contraception methods are still limited to coitus interruptus, periodic 
abstinence, condom use, or vasectomy. These methods have been criticised for being 
irreversible (vasectomy), as well as being inadequate (coitus interruptus and periodic 
abstinence – [1]). Furthermore, condoms are typically used in casual sexual encounters or 
the early stages of a relationship, and are often abandoned once a relationship becomes 
„serious‟ [2]; they have also been criticised for having an unacceptably high failure rate [3, 4]. 
Female methods, on the other hand, have been shown to be more reliable and successful, 
especially since the introduction of the female pill in the sixties. Nonetheless, 50% of the 
1,000,000 conceptions occurring daily have been reported to still be unplanned [5]. At times 
of governmental pleas for declining birth-rates around the globe, and observed changes in 
the traditional gender roles in family life, the development and introduction of a male 
contraception pill, which interestingly according to Manetti and Honig  [6] predated the 
female pill through research on the effects of testosterone on the suppression of 
spermatogenesis in 1939, “…..is surely long overdue”; especially since “men enjoy the 
pleasures of sex, but can do little to contribute to the task of family planning” [5].  
For decennia, researchers have recognised the importance of developing less invasive, 
more reversible and tolerable methods of male contraception ideally with success rates 
equivalent to those of female contraception. Consequently, pharmaceutical research has 
continued to improve the substances necessary for this ideal male „pill‟.  In a recent review, 
Manetti and Honig [6] presented the outcomes of these studies and listed the pros and cons 
of 16 male hormonal contraceptive options in four different clusters (testosterone, 
testosterone-progestin combinations, testosterone with GnRH analogues and selective 
androgen receptor modulations) which have been tested and refined in international studies 
for over 40 years in various presentations (injections, oral pill, gel, plasters, implants, etc.). 
They concluded that male hormonal contraception (MHC) is reaching the high standard set 
by the female pill and vasectomy regarding effective prevention of conception, and is as 
such pharmacologically ready for implementation. Nonetheless, a marketable male pill 
remains elusive and unavailable for the general public [7]. Why this is remains a mystery. 
According to Manetti and Honig [6] this is due to concerns around long-term effects and 
male health implications. However surely that would be very unfair considering that the 
female pill was introduced to the market less than ten years after its development, with 
refinement taking place alongside its use in practice during which side-effects and health 
problems became apparent. Does this mean that the image of the man as „Supermensch‟ 
and the woman as second-class citizen is still very much alive in the 21st century?  
On the whole, one does not seem to follow this line of reasoning, since academics 
mostly refer to the socio-political facets and the underlying psychosocial cultural factors that 
play a role in the unmarketable pill [7]. It is the latter factors and their involvement in 
generating the powerful barriers that are able to hinder the production and marketing of this 
contraceptive product which form the focus of this article. In addition, ways forward are 
presented in order to consider current research that is underway to aid progression in MHC 
implementation.  
 
Method 
A literature search was carried out on the following seven data bases: PsychINFO, ASSIA, 
Scopus, ScienceDirect, Ingenta, Medline and ISI for the time period 1990-2012. Several 
combinations of the following search words were used: male pill, male hormonal 
contraception, MHC, attitudes, and psychology. The papers were read and re-read until the 
most important findings started to emerge, which were subsequently summarised under the 
following themes: 1. acceptability; 2. trust; 3. fear of side-effects; 4. perceptions of 
contraceptive responsibility; and 5. fear of losing connotations of masculinity. 
 
1. Psychosocial and Cultural Factors 
1.1. Acceptability 
A sizeable body of research has focused on attitudes and acceptability of a male 
contraceptive pill. These studies have either examined the attitudes of those participating in 
MHC trials [8-11] or asked respondents about the hypothetical concept of a male 
contraceptive pill being made widely available to the public [12-14]. Both types of studies 
have yielded largely encouraging results, as is revealed in the following sections.   
  
1.1.1. Hypothetical Acceptability 
Whilst primarily regarding the hypothetical response, Hoesl et al. [1] carried out a 
literature search of PubMed publications. They reported on cross cultural surveys, 
conducted in Scotland, China and South Africa by Anderson and Baird [15] and Martin et al. 
[16], which showed that the majority of females across these cultures generally accepted the 
possibility of a male pill, with 87% feeling it would serve as a viable means of contraception. 
Males also agreed with and accepted the usefulness of a new method of male contraception. 
However, there was a disparity across the three cultures regarding the form of 
administration, with Scottish males preferring an oral presentation over implants, whereas 
the oral option proved the least favourable amongst Chinese males. This is in line with a 
study conducted by Weston et al. [13], who found similar disagreement regarding the 
method of administration. Based on a survey comparing seventy-six English speaking 
fathers born in South-East Asia or the Indian sub-continent with 116 Australian-born fathers, 
the study revealed that  the former  most preferred the two-yearly injected method, 
compared to the Australians, who preferred the daily oral pill. Interestingly however, the daily 
oral pill was the second most-favoured method of administration amongst the Asian males, 
which appears to contradict Hoesl‟s reported results that showed this to be the least 
favourable amongst Chinese males. This elucidates the problem of comparing such studies, 
especially when researchers offer the possibility of different options of administration of this 
new form of contraception. If all studies into the acceptability of MHC were to present the 
same options, then a more coherent conclusion could follow. Nevertheless, despite these 
issues of difference, studies seem to agree upon the general hypothetical acceptability 
across cultures.  
Oudshoorn [17] explained the difference in form of presentation, especially regarding 
injection, by an East-West divide. She showed that in Western countries, injections are 
perceived as a painful and frightful “bodily intrusion and internal violation” (p. 216). In the 
East on the other hand, injections have positive connotations as representing the 
technological expertise of the West, and are perceived as a powerful tool for delivering drugs 
into the bloodstream, in turn making a person stronger. 
 Unfortunately, some studies conducted in England did not look at different forms of 
presentations either, but did study acceptability in association with gender and type of 
personal relation. Thus, Brooks [12] examined the views of 115 males in Bristol in the south 
west, and found that the contraceptive pill was well accepted, especially amongst males in 
established relationships. These results were similar to those of Eberhardt et al. [14]. In their 
age- and gender-matched sample of 110 males and 110 females in the north east of 
England, women on the whole had a more positive attitude than men; however, males in a 
stable sexual relationship were more willing to accept the male pill than those in unstable or 
casual sexual relationships.  
 
 
1.1.2. Acceptability in Clinical Trials 
Several studies have looked at acceptability while using MHC in actual clinical trials, 
in order to further the insight into the advantages and disadvantages of the variant 
combinations of hormonal substances in contraception, and their different forms of 
presentation. Amory et al. [18] looked at the acceptability of a male contraceptive 
administered using a testosterone gel in combination with three-monthly 
depomedroxyprogestorone (DMPA) injections. The longitudinal trial by 38 healthy men in 
America over 24 weeks showed that 50% were satisfied with this method and 45% showed 
interest in using it if it were made available commercially. Remarkably, a significant 
interaction was found between current use of contraception in relationships and satisfaction 
with the regimen, with participants whose partners were using intrauterine devices more 
likely to be dissatisfied with MHC compared to couples using other methods of 
contraception. In addition, older men were more in favour of this method than younger men.  
Merrigiola et al. [8] conducted a randomised controlled trial with 122 Italian men, 75% 
of whom were in stable relationships. One group was given an injectable male contraceptive 
regimen of norethisterone enanthate and testosterone undecanoate, and a control group 
received no treatment. Of the fifty men who received the injection, six men harboured 
complaints regarding the administration method, and stopped the treatment. However, all of 
the remaining forty-four participants indicated that they rated the injection method highly, and 
none suggested that the method was unacceptable. Nonetheless, fourteen of the men stated 
that the injection was the biggest disadvantage, followed by eleven being unhappy with the 
lack of protection against sexually transmitted infections. This led to the authors concluding 
that more research into the consideration of alternative administration methods or 
presentation (oral contraceptives, patches, etc.) is necessary, in order to accommodate the 
complaints of the tested subjects. 
Sjögren and Gottlieb [11] followed 25 men in Sweden in a one-year trial of 
testosterone enanthate as part of a WHO centred study.  When interviewing the participants, 
it emerged that their attitudes towards this method of male contraception were generally 
positive, with more than half expressing the opinion that it would offer greater freedom and 
security as well as a more satisfying sex-life. Once again, however, there were five 
participants who complained about the method of injection and four showed signs of 
increased aggression during the trial period. The men‟s wellbeing remained constant 
throughout the trial; although the authors do recommend that there should be further 
research into or deliberation on the aforementioned increase in aggression and whether this 
is directly related to the method of administration. 
There are practical issues which impact upon the acceptability of MHC. For one, the time 
until spermatogenic suppression sets in is relatively long and variable; there is no safe 
interval from treatment initiation to the cessation of other forms of contraception, which 
means that there is a risk of contraceptive failure in the initial months after administering 
MHC [19]. However, this is also the case for vasectomy; thus, in a similar way to that 
following vasectomy, men need to be told to use additional forms of contraception for the 
first three to four months after starting MHC. Furthermore, in a small number of men, 
spermatogenic suppression is not achieved at all [4]. However, universal suppression of 
sperm output in all men may be an unrealistic expectation, and thus MHC may not be 
suitable for a small subgroup (minority) of men [20]. 
Apart from a delay until the contraceptive starts working, there is also the issue of a delay of 
fertility return of between three and four months [19-21] once MHC is stopped. Nieschlag 
[22] suggests that the relatively long delay until spermatogenesis is suppressed, and the 
relatively long recovery phases seem to be inherent features of MHC, which implies that this 
type of contraception would be best suited to couples in stable sexual relationships who are 
committed to long-term family planning. 
1.1.3. Summary 
Even though both types of studies have yielded largely positive results regarding 
acceptability, attitudes towards the possibility of a male contraceptive pill seem to vary 
across research projects in various cultures, in line with the outcome of a multinational 
survey [23] which reported an average acceptance rate of 55%. Hence, although there is a 
majority in favour of MHC, it is somewhat slim and results are largely based on quantitative 
studies in relatively small sub-samples of cultures. Average acceptance rates do not take 
into account contextual factors such as culture, type of relationship, or presentation of MHC. 
Therefore, further exploration is necessary through the inclusion of qualitative studies in a 
broader cultural setting, examining these contextual factors more closely.  
 
1.2. Trust 
Another psychosocial variable which has been studied in relation to the male pill is 
trust. Would women trust their partners to use a male pill efficiently, and would men trust 
themselves? Glasier et al. [24] researched the attitudes of 1,894 women in Scotland (450), 
China (900) and South Africa (544), and found that only 36 women (2%) believed that they 
would not trust their partners, which threatens the idea that new forms of male contraception 
would not be successful for reasons of trust.This is contradictory to the findings of Eberhardt 
et al. [14], who found, in their aforementioned sample of men and women in the north east of 
England, that women had less trust that men would use the male pill effectively than men 
themselves, despite there also being a lack of confidence in its effective use amongst these 
men, especially in casual relationships. Their results also revealed that being female and 
having trust in men's effective use of the male pill reliably predicted a positive attitude, while 
being male, being involved in casual sexual relationships or in no relationship, and having 
low trust in its effective use each reliably predicted a negative attitude. This might present a 
potential barrier towards its uptake, once being made available to the public. Although 
women‟s concerns may not be surprising, considering that the outcome of a man‟s 
contraceptive failure will be borne by the female partner [7], the exact reasons for this lack of 
trust are unclear.  
Oudshoorn [17] demonstrated via a critical analysis of a WHO press release and 
articles in several major newspapers in the Netherlands and Britain, that the media have 
portrayed users of MHC as unreliable. The images of MHC users constructed by journalists 
simultaneously contest and reproduce hegemonic cultural representations of masculinity. 
Oudshoorn argues that these images have served to legitimate the hegemonic view of 
gender roles, in which both the responsibilities and the risks that come with contraceptive 
use are delegated to women.  Even though the WHO‟s press release gave the green light for 
the marketable distribution of the male pill, the journalists considered themselves experts 
and warped the positive results of three decades of research into negative fabrications: 
“Whereas the WHO press bulletin tells the story of a very promising, highly effective new 
male contraceptive in which men are the heroes, the news media tell stories in which side-
effects and pain are the most important topics, and in which men are portrayed as victims” 
(p.200).  Oudshoorn [17] used examples such as a headline from „De Haagse Post‟: 
“Women will not Trust Men” (p. 201), even though there was no mention of this in the WHO‟s 
press release, and stories from journalistic interviews  which were published such as: 
“Women don't trust men with this, they want to keep it in their own hands.  Imagine that you 
have to control your partner: „Darling, did you take your injection?‟ [...] I'm afraid that this is 
again a feminist victory that is good for nobody" (p. 201).   
 Academically, a trust-related psychological factor which has been studied by Reis et 
al. [25] and Eberhardt et al. [14] is self-efficacy, which is a theoretical construct representing 
the belief that one is capable of making the correct decisions in order to come to the desired 
outcome. With regard to trust, this means that once a male has the self-belief to take 
responsibility for the contraception in sexual interaction, he will adhere to the prescriptions of 
proper use and will at least trust himself to do so. High self-efficacy in heterosexual females 
has been reported as resulting in more effective use of contraceptives [25].  Furthermore, 
Eberhardt et al. [14] found that men in stable relations were more likely to have high self-
efficacy and a more positive attitude towards the male pill.    
 
1.3. Fear of Side-Effects 
Another factor shaping the social representation of MHC are the possible side-effects 
caused by its use. Such concern has been found to potentially affect acceptability and 
willingness to use MHC. Oudshoorn [17] criticised the construction of standards to assess 
the side-effects of contraceptives in males as dependent on the gendered cultural norm 
regarding acceptability of risks. Rather than looking for a balanced risk-benefit assessment, 
as has been carried out for the female equivalent (risks vs. benefits of avoiding pregnancy, 
abortions, etc.), for the male pill one is looking for zero risk in which men are compared with 
healthy men. She also emphasised that every drug has side-effects; one must seek to 
balance these with the positives rather than exhaustively trying to drill them out. Ideally, she 
promoted a shared risk model, in which both risks and benefits of men and women are 
looked at. For example, she reported on the men in Ringheim‟s [26] publication who 
indicated in their interviews a wish for a male pill to take away the risks that their wives had 
been burdened with: “My wife taking estrogens was like the shrew that couldn‟t be tamed. 
She would wake up depressed…and after a period of time I said, “Honey, it‟s the Pill, stop 
taking it, I don‟t care, I‟ll use condoms, or other forms of birth control, I‟ll go on the program 
that my friend is on, but you stop taking the Pill right now” (p.76).  
Several studies revealed that respondents have a fear of side-effects. Brooks [12] 
found that 70% of respondents would not tolerate any side-effects, although their attitudes 
towards an effective male contraceptive were positive. Similar findings were reported by 
Weston et al. [13] and Heinemann et al. [23], in that any side-effects caused by methods of 
male contraception would not be desirable. More recently, in a mixed-method study in the 
East of England, Walker [27] explored attitudes towards the male pill and found that 
participants who were unwilling or undecided regarding MHC were more likely to be 
concerned about potential effects of the male pill on future fertility. 
O‟Connor, Ferguson and O‟Connor [28]) carried out two studies within the theoretical 
model of framing effects in health behaviour [29]. In this model, it is claimed that when a 
behaviour is seen as involving a certain degree of risk, a loss-frame advantage is observed. 
For behaviours that are perceived as involving less risk or are considered as safer, a gain-
frame advantage is revealed. Considering this, it is evident that the use of a MHC as a 
prevention behaviour is regarded as more risky than other prevention behaviours (e.g. using 
sun cream), and so a loss-frame advantage should be observed. O‟Connor et al.‟s [28] first 
study, involving a British sample of 46 males and 55 females, examined how risky two 
methods of administration of male hormonal contraception (oral pill and injection) were 
regarded in comparison to other prevention behaviours, such as using a condom and using 
sun cream. The males reported finding the two forms of hormonal contraception more risky 
than the women did, yet both men and women perceived condoms as involving less risk 
than hormonal contraception. Regarding hormonal contraceptives specifically, men saw the 
injection method to be riskier than the oral pill, whereas women saw no difference in risk 
between the two. These data suggest that women are less likely to consider new forms of 
male contraception as risky, perhaps due to the women‟s pre-acquaintance with and regular 
use of hormonal contraception, whereas for men it remains a novelty shrouded in mystery. 
On a different note, differences in health behaviours (e.g. taking vitamin supplements 
or going for regular medical checkups) seem to be important in relation to male hormonal 
contraception: men are known to take less care (as a trait of masculinity [30]) or to overly 
take care (being scared of any unexpected bodily change such as possible side effects) of 
their health [14, 17]. Eberhardt et al. [14] linked the fear of side effects to the assessment of 
health behaviours with the hypothesis that the more a person‟s behaviour is healthy or 
health-orientated, the more worried the individual will be about possible side-effects.  Even 
though they did find that high perceived self-efficacy was associated with engagement in 
health related behaviours, there was no such relation with concerns about those effects. 
They found more support for men's masculine role in that those men who did not show a lot 
of interest in their health also did not show any enthusiasm for the availability of the male pill.  
This shows that it is unclear as to whether health consciousness is likely to influence uptake 
of MHC.   
 
1.4. Perceptions of Contraceptive Responsibility 
In the twentieth century the majority of developments in reproductive medicine have 
moved from a male to a female-dominated field [17]. For over five decades, women have 
been using the hormonal contraceptive pill, which, as stated earlier, was introduced after ten 
years of research. Associated health risks have been reported over the years, such as an 
increased likelihood of breast cancer, weight gain, vascular thrombosis, heightened blood 
pressure, etc. Research into the use of the male contraceptive pill has been carried out since 
the 1970s, and hundreds of trials have been conducted in order to augment the pill‟s 
performance in terms of side-effects and risk factors. Changes in family relations, the 
emancipation of women and changes in male attitudes towards health and wellbeing are all 
considered to provide the platform upon which a change in the gender issues of 
contraceptive responsibility can take place. These social changes have prepared the way for 
the commercial introduction of MHC. Regardless of over forty years‟ worth of progressive 
research and social changes however, there is still no commercially available male 
contraceptive pill.  
Several studies have looked into the attitudes across both genders regarding 
contraceptive responsibility. Anderson, Kinniburgh and Baird [31] concluded their review by 
arguing that there is an increasing awareness that men should share contraceptive 
responsibility. They also argued that it may well be that the recent surge in understanding 
reproductive function on a molecular basis  will reveal the benefits of MHC and allow men to 
have more control over the outcome of their fertility in sexual relations. According to Glasier 
et al. [24] the majority of men responding to a survey, believed that they should be more 
responsible for contraception than they were. It has also been asserted that a high 
proportion of men from developed as well as developing countries are prepared to use a 
hormonal method once it is made available [32]. This shared responsibility was also 
demonstrated by Oudshoorn [17], who quotes one of the men in Ringheim‟s study: “If she 
goes on the Pill again there is always the risk, isn‟t it? And my way of thinking is, once she‟s 
taken the risk for a few years, I‟ll take the risk. Then you halve it.” (p.8 [33]). It is worth noting 
that similar motivations have been reported to play a role in the decision to undergo 
vasectomy; however, the procedure is often delayed due to its unfamiliarity and irreversibility 
[34]. 
In Glasier et al.‟s [24] own study, 994 women who attended family planning clinics 
were selected from Edinburgh, Shanghai, Hong Kong and Capetown. There were marked 
differences between the responses from these cities that drove the authors to conclude that 
at that time, the male pill would be less popular in the far-East than in the West. Additionally, 
they found that contrary to initial beliefs, the male pill may serve a significant purpose in 
Africa. However, the authors also concluded that according to the participating women, a 
higher number of options of contraceptive methods would allow an increased number of men 
from all countries to take a greater responsibility regarding their sexual health and 
contraception, suggesting that in order to accommodate the cultural differences in 
contraceptive preference, it is necessary to develop and distribute more than just one form of 
MHC administration. 
 The authors also showed that people‟s beliefs about contraceptive responsibility had 
changed considerably from the 1960s to the 1990s. They refer to the American study carried 
out by Bardwick [35] who interviewed 107 women, of whom 72% stated that they wanted full 
control of contraceptive responsibility, and 16% preferred the men to take such 
responsibility, whilst only 12% believed the responsibility should be shared between males 
and females. However, a telephone survey carried out by the Henry J. Kaiser Family 
Foundation [36] of 105 Americans thirty years later, found that more than 70% of both men 
and women indicated that men should play more of a role in contraceptive responsibility. 
Other studies [37, 14] have found that men in stable sexual relationships in particular, 
are more willing to take contraceptive responsibility. It is more likely that they will use the 
male pill once it is available. This may be due to the fact that they have regular sexual 
intercourse, as men who are not in relationships may on average engage in less sexual 
activity and may therefore consider the need for regular contraception as unnecessary, 
preferring condoms as a more suitably practical alternative. Furthermore, men in stable 
sexual relationships are more likely to be committed to their relationship than those in casual 
relationships. As is discussed in the next section, another explanation might be that the 
masculine stereotype is challenged when in a stable sexual relationship: the sensitivity in a 
„hegemonic male‟ may surface when awareness of the potential risk of side-effects that their 
female partner faces becomes clear. Alternatively, it may be the instinctive masculine trait of 
protecting their female partner that results in the man taking the full contraceptive 
responsibility.  
 
1.5. Fear of Losing Connotations of Masculinity 
Another factor that may explain the lack of commercially available MHC is the 
suggestion that men may not be enthusiastic about its use because of its feminine 
association. As the Pill has been readily available to women for decades now, but there is 
still no male version, many men- particularly those who consider themselves as 
stereotypically masculine- will feel that using a form of MHC would threaten their masculinity 
by performing a role considered feminine in the context of a stable sexual relationship. In 
addition, an important factor in determining masculinity for men themselves is sexual 
performance and more significantly fertility. Since the role of MHC will be to decrease or stop 
the rate of fertility, this again may be perceived by men as threatening the status of 
traditional, hegemonic masculinity. Concerns around fertility and virility were highlighted in a 
study by Kalampalikis and Buschini [38], in which 46 semi-structured interviews were carried 
out with males and females in various sorts of relationships to understand how they 
constructed the male pill. They concluded that individuals used the female pill to inform their 
expectations of the advantages and disadvantages of the as yet imaginary male pill. 
Furthermore, virility was very important to men, as a sign of being manly and potent. MHC 
was seen as a threat to manhood – which, according to the authors, is possibly the reason 
why the male pill remains in the sphere of a medical promise rather than a medical reality. 
An example of the masculine stereotype has also been shown by Oudshoorn [17]: 
“We all know that at this stage of time, it‟s not socially acceptable for men to use male 
contraception” [32] and “You still get people who would say „What are you doing that for, 
can‟t your wife take the Pill or something?‟ It seems like the abnormal rather than the normal, 
the idea that the bloke, apart from condoms, would actually take any part of sexual 
responsibility for contraception, particularly not one which involved needles” [32]. These 
quotes from qualitative studies are powerful examples of how stereotypes influence male 
attitudes, with many choosing to reject new forms of male contraception in favour of 
safeguarding their masculinity. Interestingly though, as mentioned in section 1.4, some 
males are in favour of sharing responsibility whilst maintaining a masculine disposition. This 
is mainly evident in cases where a man‟s female partner complains about side effects, in 
which case the man will wish to protect his partner and take over the contraceptive role. 
 Furthermore, due to the recent social changes causing somewhat of a shift from 
male dominance towards the emancipation of women, many men are starting to openly 
exhibit traits such as sensitivity in abandoning the hegemonic masculinity that has 
dominated relationships in the past. As one man in Ringheim‟s study observed: “I think that 
men have always had soft sides, gentle sides, nurturing sides, but for a long time they have 
been repressed. To a certain extent all these norms, morals, and values are raised into 
prominence because we are precisely in that period of change so people are forced to think 
about „Do men have to do things a certain way?‟ and „What‟s a typical male?‟ [32]. 
 
2. Future Directions 
Research into new forms of male contraception is progressing. Recently, advances in the 
development of non-hormonal methods have been reported. Mruk [39] and Cheng and Mruk 
[40] reviewed these developments, examining research into methods such as reversible 
inhibition of sperm under guidance, contraceptive vaccines, and Ca++ channel blockers. They 
concluded that several of the reviewed approaches showed promise, and that with some 
additional research a safe, effective, reversible and affordable male contraceptive could be 
brought to the market. The application of a further non-hormonal method, epididymal 
protease inhibitor, is reviewed by O‟Rand et al. [41]. 
With regards to hormonal methods, a recent study by Nieschlag et al. [42] demonstrated 
successful use of testosterone undecanoate in men with normal as well as those with 
subnormal sperm counts; this broadens the range of potential users of MHC. Overall, these 
developments are encouraging, because they show that, once available, there should be a 
variety of methods of male contraception for potential users to choose from. 
The Teesside Research Group is momentarily committed to carrying out studies to 
understand how attitudes towards MHC can be changed in men as well as in women. This is 
achieved by collecting and comparing longitudinal data before and after presenting 
scenarios of positive responses to MHC at various points: immediate, three months, six 
months, nine months and one year. If Oudshoorn [17] is correct about the effects on the 
layperson‟s attitudes and their relation to negative publicity in the media, outcomes reflecting 
positive attitudes which remain over a longer period of time are to be expected.   
  In further prospective research, the Teesside Research Group will be carrying out 
qualitative research to elicit individual discourses across various cultures. This entails 
individual reflections of males and females of different ages and in differing sexual 
relationships (casual/stable), on the advantages and disadvantages of the introduction of a 
new male hormonal contraception. The quotes in Ringheim‟s studies of the 1990s were very 
powerful and distinct from quantitative outcomes of the WHO studies or the results as 
presented by the Edinburgh Group [16, 24]. A similar interesting revelation of individual 
accounts is to be expected from Ringheim‟s studies, especially considering that more than 
twenty years have passed since they were conducted. If anthropologists and sociologists 
[43-48] are right that the ideological stance towards gender in families has changed in recent 
years in that men and women are more willing to share contraceptive responsibility and are 
less affected by traditional gender-role stereotypes, then a change in expressions of their 
attitude towards contraception should be noticed.   
 A third study that the research group are looking into is a content analysis of the 
changes in press coverage of MHC in the last half-century, which reflects the attitudes of the 
media and what knowledge or truths they choose to divulge regarding studies that have 
been conducted. As has been stated before, Oudshoorn [17] believed that the media 
exhibits their own truth, their own perspective upon issues and this can have a devastating 
effect upon the subject, via communicating an often „false‟ or distorted picture to the general 
public. 
 More importantly, we need more studies in which different forms of presentation of 
the MHC are used consistently. As shown in this chapter, there is an absence of consistency 
in the various methods, substances and forms of administration used in the studies as a 
whole, which makes comparison between these virtually impossible. In order to gain a 
proper understanding of psychosocial and cultural effects upon a new form of male 
contraception, the studies should employ similar option choices of MHC, and contextualize 
these in the psychosocial and cultural factors relevant to its acceptability. It may be 
necessary to develop a framework, or a matrix, in which these major factors are included, 
which would allow for aggregating the data yielded by research in a number of contexts in a 
structured way. 
 Furthermore, it is clear from the aforementioned studies as well as from a study 
conducted by Naz and Rowan [49] that no single method will be acceptable to all men and 
women in all cultures, for there is no absolute consensus regarding which form of MHC acts 
as the most preferable. For this reason, a range of options is necessary to make MHC 
universally marketable- just as a male presently has the choice of condoms or vasectomy, 
so should he have the choice of substances as well as presentation of MHC (injection, oral 
pill, implant etc.). As Manetti and Honig [6] have discussed in their review, there are notable 
differences to be found between cultural populations regarding MHC presentation. For 
example, the endocrine response to the use of testosterone as a male contraceptive was 
significantly more effective for Asian than for Caucasian participants. A variation in body fat 
content has been suggested as one of the explanations for this ethnic difference, but not 
been examined. Liu, Swerdloff and Wang [20] express their confusion regarding the overall 
effects of ethnicity regarding the differences in the suppressed sperm output, since variation 
between Caucasian and Asian men has been revealed in their reviewed studies. For that 
reason they conclude that it seems unlikely that universal suppression of sperm output in all 
men can be realistically expected. Hence, in order for there to be a viable means of 
distributing MHC whilst considerate of difference in preference, more cross-cultural research 
is needed, with the assumption that this will result in clear culture-specific findings as to 
„who-wants-what‟.  
Additionally, an integrated model of psychosocial and cultural factors shaping 
attitudes towards the male pill is required in order to evaluate the overall psychosocial 
variation which distinguishes men from each other (e.g. high vs. low self-efficacy, fear of 
side-effects, cultural socialisation, degree of masculinity, etc.) in their uptake of MHC. 
Further research should add to existing knowledge in order to be able to facilitate the 
construction of such a model. Research from a psychological point of view could look at the 
role of self-efficacy in the context of clinical trials, in order to gain a greater understanding of 
men‟s self-efficacy and whether this will affect efficient use of contraception. In addition, 
further investigation could lead to tailoring education programmes to take the various levels 
of men‟s self-efficacy into account. From a social point of view, societal norms undermining 
the acceptability of MHC need to be drawn attention to and questioned, through continued 
research and dissemination of findings. Such research needs to inform the marketing and 
promotion of a male contraceptive once it becomes available, since it would help address 
these norms and tailor the promotion of MHC accordingly.  
Finally, a better understanding of such a model would help inform health-promotion 
campaigns as well as educational programmes which aim to facilitate a more emancipatory 
approach to family relations regarding choices of contraception. It must be acknowledged 
that most likely changes in legislation, business practice and public administration will also 
be required to effect such changes, which in turn would necessitate a shift in societal norms 
and political decisions. However, health-promotion campaigns provide a potential starting 
point from which such changes can take place; such campaigns are designed to inform the 
individual, thereby allowing them to make an educated choice. Applied to the uptake of 
MHC, if an increasing number of men choose to use hormonal or non-hormonal male 
contraceptives, this may gradually stimulate a shift in social norms, thereby making the use 
of MHC more acceptable. 
As Liu and McLachlan [7] emphasise, research and trials have exhausted their worth 
and the focus should mainly be upon distribution. Marketable forms of MHC should be made 
available so that research can be transferred to real-life as opposed to clinical trials, in order 
to refine and develop the ultimate product along the same lines as its female equivalent. This 
is especially significant because of the effect of randomised control trials using control 
groups carrying a high-risk of unwanted pregnancies due to the application of a placebo. 
Since the research has been ongoing for over forty years, there is a high degree of 
confidence that MHC will be effective, and should therefore be distributed. It is disappointing 
however, that distribution has yet failed to occur. Although pharmaceutical companies were 
actively involved in research and development of MHC for some time [17], the major 
pharmaceutical sponsors of this research have recently withdrawn their support in this area 
of product development, which has resulted in difficulties in completing the final phases of 
clinical development [4]. Pharmaceutical companies still have reservations about research 
and development of MHC, most likely due to the fact that it is difficult to predict how well 
these products will be accepted by men and, consequently, how profitable they will be [39]. 
As Wang and Swerdloff [50] state, since MHC is efficacious, reversible and well-tolerated for 
a target population of younger men, it is time for industry and government to work together to 
make it commercially available.  
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